EyePoint Pharmaceuticals Inc
EYPT9.940USD
+0.230+2.37%
交易中 （美东）报价延迟15分钟
683.98M总市值
亏损市盈率 TTM
关于 EyePoint Pharmaceuticals Inc 公司
EyePoint Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司。该公司专注于开发和商业化用于治疗眼部疾病的眼科产品。该公司的产品线利用其 Durasert 技术 (Durasert) 进行持续眼内药物输送，包括输送 EYP-1901，这是一种针对抗血管内皮生长因子 (anti-VEGF) 介导的视网膜疾病的试验性持续输送治疗。其其他产品线计划包括 EYP-2301，一种有前途的 TIE-2 激动剂，razuprotafib，以 Durasert E 配制，可能改善严重视网膜疾病的结果。EYP-1901 目前处于 2 期临床试验阶段，作为湿性老年性黄斑变性 (wet AMD)、非增生性糖尿病视网膜病变 (NPDR) 和糖尿病性黄斑水肿 (DME) 的持续输送治疗。该公司的其他产品包括 YUTIQ 和 DEXYCU。
公司简介
公司代码EYPT
公司名称EyePoint Pharmaceuticals Inc
上市日期Jan 27, 2005
CEODr. Jay S. Duker, M.D.
员工数量165
证券类型Ordinary Share
年结日Jan 27
公司地址480 Pleasant Street, Suite C400
城市WATERTOWN
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02472
电话16179265000
网址https://eyepointpharma.com/
公司代码EYPT
上市日期Jan 27, 2005
CEODr. Jay S. Duker, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
685.61K
+1.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
575.46K
+1.97%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
142.86K
+567.59%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
117.28K
+1.73%
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
107.43K
+977.87%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
45.01K
--
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
41.78K
--
Dr. Reginald J Sanders, M.D.
Dr. Reginald J Sanders, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Fred Hassan
Mr. Fred Hassan
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stern
Mr. Stern
Investor Relations
Investor Relations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
685.61K
+1.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
575.46K
+1.97%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
142.86K
+567.59%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
117.28K
+1.73%
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
107.43K
+977.87%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
45.01K
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2024
FY2023
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
YUTIQ
3.10M
7.16%
地区USD
名称
营收
占比
United States
42.05M
97.17%
China
1.12M
2.60%
United Kingdom
100.00K
0.23%
业务
地区
业务USD
名称
营收
占比
YUTIQ
3.10M
7.16%
股东统计
更新时间: 7月25日 周五
更新时间: 7月25日 周五
持股股东
股东类型
持股股东
持股股东
占比
Cormorant Asset Management, LP
12.10%
Suvretta Capital Management, LLC
9.89%
Adage Capital Management, L.P.
9.01%
BlackRock Institutional Trust Company, N.A.
7.19%
Franklin Advisers, Inc.
5.99%
Other
55.83%
持股股东
持股股东
占比
Cormorant Asset Management, LP
12.10%
Suvretta Capital Management, LLC
9.89%
Adage Capital Management, L.P.
9.01%
BlackRock Institutional Trust Company, N.A.
7.19%
Franklin Advisers, Inc.
5.99%
Other
55.83%
股东类型
持股股东
占比
Hedge Fund
39.71%
Investment Advisor
28.58%
Investment Advisor/Hedge Fund
22.88%
Venture Capital
7.91%
Research Firm
5.09%
Private Equity
4.39%
Individual Investor
3.52%
Bank and Trust
1.52%
Pension Fund
0.40%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
384
78.48M
114.05%
-10.35M
2025Q1
386
76.27M
110.90%
-11.90M
2024Q4
373
75.75M
111.39%
+202.32K
2024Q3
358
60.55M
112.89%
-8.01M
2024Q2
345
60.80M
116.35%
-2.75M
2024Q1
328
57.32M
114.97%
+528.95K
2023Q4
282
52.72M
108.16%
+11.49M
2023Q3
239
37.39M
106.16%
-1.26M
2023Q2
224
35.30M
102.90%
-4.83M
2023Q1
220
33.02M
96.37%
-5.12M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Cormorant Asset Management, LP
8.32M
12.1%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
6.80M
9.89%
+21.00K
+0.31%
Mar 31, 2025
Adage Capital Management, L.P.
6.20M
9.01%
+450.00K
+7.83%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.95M
7.19%
+206.82K
+4.36%
Mar 31, 2025
Franklin Advisers, Inc.
4.12M
5.99%
+9.56K
+0.23%
Mar 31, 2025
The Vanguard Group, Inc.
3.82M
5.55%
+31.14K
+0.82%
Mar 31, 2025
Federated Hermes Global Investment Management Corp.
3.71M
5.39%
+2.50K
+0.07%
Mar 31, 2025
TCG Crossover Management, LLC
3.57M
5.19%
--
--
Mar 31, 2025
RA Capital Management, LP
3.18M
4.62%
--
--
Mar 31, 2025
Citadel Advisors LLC
2.29M
3.32%
-180.78K
-7.33%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.96%
SPDR S&P Pharmaceuticals ETF
0.79%
Simplify Health Care ETF
0.57%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.56%
Federated Hermes MDT Small Cap Core ETF
0.37%
iShares Micro-Cap ETF
0.13%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
iShares Russell 2000 Value ETF
0.04%
Avantis US Small Cap Equity ETF
0.04%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.96%
SPDR S&P Pharmaceuticals ETF
占比0.79%
Simplify Health Care ETF
占比0.57%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比0.56%
Federated Hermes MDT Small Cap Core ETF
占比0.37%
iShares Micro-Cap ETF
占比0.13%
ProShares Ultra Nasdaq Biotechnology
占比0.07%
Invesco Nasdaq Biotechnology ETF
占比0.07%
iShares Russell 2000 Value ETF
占比0.04%
Avantis US Small Cap Equity ETF
占比0.04%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
公告日期
类型
比率
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
